Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $27.89, for a total transaction of $261,831.32. Following the completion of the transaction, the chief financial officer owned 264,117 shares of the company's stock, valued at $7,366,223.13. The trade was a 3.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Oluyemi Okupe also recently made the following trade(s):
- On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.09, for a total transaction of $1,943,389.47.
- On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87.
- On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The stock was sold at an average price of $34.03, for a total transaction of $619,243.91.
Hims & Hers Health Stock Down 4.1%
Hims & Hers Health stock opened at $27.43 on Wednesday. The firm has a 50 day simple moving average of $32.10 and a 200 day simple moving average of $26.05. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $65.30. The firm has a market capitalization of $6.40 billion, a price-to-earnings ratio of -43.53 and a beta of 2.40.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company had revenue of $753.21 million for the quarter, compared to analysts' expectations of $698.90 million. During the same quarter in the prior year, the company earned $0.17 EPS. The company's revenue was up 38.2% on a year-over-year basis. On average, analysts predict that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.
Institutional Investors Weigh In On Hims & Hers Health
Several large investors have recently added to or reduced their stakes in the business. Binnacle Investments Inc purchased a new position in Hims & Hers Health during the third quarter worth about $28,000. Versant Capital Management Inc raised its holdings in shares of Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company's stock valued at $26,000 after acquiring an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock valued at $27,000 after acquiring an additional 319 shares in the last quarter. Silicon Valley Capital Partners bought a new stake in shares of Hims & Hers Health during the 3rd quarter valued at about $48,000. Finally, Bogart Wealth LLC boosted its position in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after acquiring an additional 632 shares during the last quarter. Institutional investors own 63.52% of the company's stock.
Hims & Hers Health News Roundup
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations, arguing that the agency misunderstands the company’s data-sharing and subscription practices. He also said compounded GLP-1 medications helped lower treatment costs, potentially supporting the company’s broader affordability strategy. Hims & Hers CEO says FTC lawsuit misunderstands how the company works
- Positive Sentiment: An analysis highlighted the Eucalyptus deal as a potential way for Hims & Hers to enter new markets and broaden its international or product reach, offering a possible growth catalyst. Hims & Hers: Eucalyptus Deal Unlocks New Markets
- Neutral Sentiment: Dudum’s CNBC interview also addressed artificial intelligence, the transition from compounded to branded GLP-1 drugs and efforts to reduce healthcare costs. These initiatives could influence the company’s long-term strategy, but they do not resolve the immediate regulatory concerns. Watch CNBC's full interview with Hims & Hers CEO Andrew Dudum
- Neutral Sentiment: Analysts’ questions following the second-quarter earnings call indicate continued investor scrutiny of growth, profitability and the company’s GLP-1 strategy. The prior quarter featured strong revenue growth but a larger-than-expected loss, increasing the importance of execution. 5 Revealing Analyst Questions From Hims & Hers Health’s Q2 Earnings Call
- Negative Sentiment: The FTC lawsuit alleges improper business practices involving privacy and billing. The news previously triggered a sharp selloff, and shareholder-law-firm investigations by Hagens Berman, Kessler Topaz and Kaplan Fox are adding legal, compliance and potential securities-liability risks. FTC lawsuit and Hagens Berman investigation
- Negative Sentiment: CFO Oluyemi Okupe sold shares, including 9,388 shares on August 17. However, both disclosed sales were made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making them a limited bearish signal rather than clear evidence of deteriorating confidence. SEC insider transaction filing
Wall Street Analyst Weigh In
Several brokerages have commented on HIMS. Zacks Research upgraded Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Monday, July 13th. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a research report on Tuesday, August 11th. Needham & Company LLC increased their price target on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Morgan Stanley raised their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 11th. Finally, Jefferies Financial Group set a $24.50 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $32.43.
View Our Latest Analysis on Hims & Hers Health
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
